首页> 外文OA文献 >Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts
【2h】

Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts

机译:未成熟树突状细胞和骨髓移植诱导同种异体混合嵌合体导致对主要组织相容性复杂的同种异体移植物的耐受性延长

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mixed chimerism has been shown to lead to prolonged major histocompatibility complex (MHC) disparate allograft survival and immune-specific tolerance; however, traditional conditioning regimes often involve myeloablation, which may pose a significant safety risk. In this study we examined the use of donor C57BL/6 (H-2b) immature dendritic cells (imDCs) to tolerize the BALB/c (H-2d) recipient to bone marrow transplantation (BMT), allowing the induction of mixed chimerism without immunosuppression or myeloablation. We showed that successful mismatched bone marrow engraftment can be achieved using imDCs given up to 3 days prior to BMT and that mixed chimerism can be established and detected in excess of 100 days post-BMT without evidence of graft-versus-host disease. Furthermore, we showed that imDCs can suppress lymphocyte proliferation in response to mismatched MHC stimulation, leading to increased expression of interleukin (IL)-4 and IL-10 and decreased expression of IL-2 and interferon-γ (IFN-γ). The induction of stable chimeras through pre-conditioning of mice with donor imDCs followed by BMT led to tolerance, allowing the long-term survival (> 110 days) of mismatched cardiac allografts and the prolonged survival of mismatched skin allografts without the need for immunosuppression or myeloablation. Transplantation with third-party C3H allografts were rapidly rejected in this model, suggesting that immune-specific tolerance was achieved. The induction of immune-specific tolerance without the need for immunosuppression or myeloablation represents a significant advance in transplant immunology and may provide clinicians with a plausible alternative in combating organ rejection following transplantation.
机译:混合嵌合体已被证明可以延长主要的组织相容性复合体(MHC)不同的同种异体移植物存活时间和免疫特异性耐受性。然而,传统的调理方案经常涉及骨髓消融,这可能带来重大的安全风险。在这项研究中,我们研究了使用供体C57BL / 6(H-2b)未成熟树突状细胞(imDCs)耐受BALB / c(H-2d)受体进行骨髓移植(BMT)的过程,从而允许在不进行骨髓移植的情况下诱导混合嵌合体免疫抑制或骨髓消融。我们表明,使用BDC之前3天之前给予的imDC可以成功完成不匹配的骨髓移植,并且BMT后100天以上可以建立和检测到混合嵌合体,而没有移植物抗宿主病的迹象。此外,我们发现imDCs可以响应失配的MHC刺激而抑制淋巴细胞增殖,从而导致白介素(IL)-4和IL-10的表达增加,以及IL-2和干扰素-γ(IFN-γ)的表达降低。通过先用供体imDCs预处理小鼠然后再用BMT诱导稳定的嵌合体导致耐受,从而允许不匹配的心脏同种异体移植物的长期存活(> 110天)和不匹配的皮肤同种异体移植物的长期存活,而无需进行免疫抑制或免疫抑制。骨髓消融。在该模型中,第三方C3H同种异体移植的移植被迅速拒绝,这表明可以实现免疫特异性耐受。无需免疫抑制或骨髓消融即可诱导免疫特异性耐受,这代表了移植免疫学的重大进步,并可能为临床医生提供一个可行的替代方法,以对抗移植后的器官排斥。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号